Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers

NCT07304726 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: CKD-383 0.25/12.5/1000mg
DRUG: CKD-501, D745, D150

Sponsor

Chong Kun Dang Pharmaceutical